Trials / Completed
CompletedNCT05769946
A Study of Hemay005 in Adult With Atopic Dermatitis
A Phase II Study to Evaluate the Efficacy and Safety of Hemay005 Tablet in Adult With Moderate to Severe Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 79 (actual)
- Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A multicenter, randomized, double-blind, placebo-controlled, phase II study to evaluate the efficacy and safety of Hemay005 tablet in the treatment of moderate to severe atopic dermatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hemay005 | A PDE-4 inhibitor |
Timeline
- Start date
- 2022-11-24
- Primary completion
- 2024-01-24
- Completion
- 2024-02-21
- First posted
- 2023-03-15
- Last updated
- 2024-03-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05769946. Inclusion in this directory is not an endorsement.